DYNOGEN PHARMACEUTICALS, Inc.
TYPE OF COMPANY: Drug Development
CORPORATE ADDRESS: 31 St. James Avenue, Suite 905, Boston, MA 02116
RESEARCH FACILITY: Durham, NC
PHONE NUMBER: 617-357-8000
WEB SITE:www.dynogenpharm.com
MANAGEMENT TEAM MEMBERS:
Lee R. Brettman, M.D., FACP
Co-founder, President and CEO
Karl B. Thor, PhD
Co-founder and Chief Scientific Officer
Mark J. Fitzpatrick
Chief Financial Officer
Robert C. Lorette
SVP, Chief Business Officer
Michael W. Spellman, PhD
SVP, Pharmaceutical Development
Steven B. Landau, PhD
VP, Clinical Development
BOARD MEMBERS:
Lee R. Brettman, M.D., FACP
Co-founder, President and CEO
Dynogen Pharmaceuticals, Inc.
Karl B. Thor, Ph.D.
Co-founder, Chief Scientific Officer
Dynogen Pharmaceuticals, Inc.
Jonathan J. Fleming
Managing Partner
Oxford Bioscience Partners
Tony Scullion
CEO
Memory Pharmaceuticals Corp.
James F. White, Ph.D.
Executive VP of R & D, COO
Hypnion, Inc
Myles D. Greenberg, M.D.
Principal
A. M. Pappas & Associates, LLC
Gus Lawlor
General Partner
HealthCare Ventures, LLC
INVESTORS:
Oxford Bioscience Partners, HealthCare Ventures LLC and A.M. Pappas & Associates. Total amount raised in its Series A round was $13.25 million.
REVENUES: N/A
YEAR ESTABLISHED: Dynogen was incorporated on March 15, 2002.
NUMBER OF EMPLOYEES: 15
